Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SAN DIEGO, March 09, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, March 16, 2017 at 5:00 p.m. ET to report its fourth quarter and full year 2016 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 85799370. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
